Treatment of Depression in the Climacterium

Authors

  • Renan Rocha Coordenador do Serviço de Saúde Mental da Mulher das Clínicas Integradas da Universidade do Extremo Sul Catarinense (UNESC).
  • Joel Rennó Jr Médico Psiquiatra. Diretor do Programa de Saúde Mental da Mulher (Pró-Mulher) do Instituto de Psiquiatria do Hospital das Clínicas da Universidade de São Paulo (USP). Doutor em Psiquiatria pela FMUSP. Membro fundador da International Association for Women’s Mental Health. Médico do Corpo Clínico do Hospital Israelita Albert Einstein-SP. https://orcid.org/0000-0003-1954-5898
  • Hewdy Lobo Ribeiro Psiquiatra Forense, Psicogeriatra e Psicoterapeuta pela Associação Brasileira de Psiquiatria. Psiquiatra no Pró-Mulher do Instituto de Psiquiatria da USP.
  • Amaury Cantilino Diretor do Programa de Saúde Mental da Mulher da UFPE. Professor Adjunto do Depto. de Neuropsiquiatria da UFPE.
  • Jerônimo de Almeida Mendes Ribeiro Médico Psiquiatra. Especialista em Psiquiatria pela Associação Brasileira de Psiquiatria. Pesquisador do Grupo de Psiquiatria - Transtornos Relacionados ao Puerpério, pela Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA).
  • Renata Demarque Médica Psiquiatra. Colaboradora do Programa de Saúde Mental da Mulher (Pró-Mulher) do Instituto de Psiquiatria do Hospital das Clínicas da Universidade de São Paulo (USP).
  • Juliana Pires Cavalsan Médica Psiquiatra. Colaboradora do Programa de Saúde Mental da Mulher (Pró-Mulher) do Instituto de Psiquiatria do Hospital das Clínicas da Universidade de São Paulo (USP).
  • Gislene Cristina Valadares Médica Psiquiatra pela Associação Brasileira de Psiquiatria. Mestre em Farmacologia e Bioquímica Molecular. Membro fundador do Serviço de Saúde Mental da Mulher do HC-UFMG, do Ambulatório de Acolhimento e Tratamento de Famílias Incestuosas (AMEFI, HC-UFMG), da Seção de Saúde Mental da Mulher da WPA e da International Association of Women’s Mental Health. https://orcid.org/0000-0001-8515-0937
  • Antonio Geraldo da Silva Psiquiatra. Especialista em Psiquiatria e Psiquiatria Forense pela ABP-AMB-CFM. Doutoramento em Bioética pela Universidade do Porto - CFM. Psiquiatra da Secretaria de Saúde do Distrito Federal - SES-DF. Diretor Científico do PROPSIQ. Presidente da ABP - 2010/2013. https://orcid.org/0000-0003-3423-7076

DOI:

https://doi.org/10.25118/2763-9037.2013.v3.338

Keywords:

depression, climacterium, treatment

Abstract

In the female gender, Depression stands out due its prevalence over the reproductive years. Especially in perimenopausal women, there is significant increase in the number of cases, particularly associated with hot flushes. Several antidepressants have demonstrated similar efficacies in the general population. However, studies suggest that it is possible a thorough and specific selection of the antidepressant medication for patients who have Major Depres-sive Disorder in the climacterium associated with vasomotor symptoms.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

• 1. Soares C, Warren M. The menopausal transition: interface between gyne-cology and psychiatry. Key Issues Ment. Health. 2009;175:102-114. DOI: https://doi.org/10.1159/isbn.978-3-8055-9102-7

• 2. Soares C, Zitek B. Reproductive hormone sensitivity and risk for depresion across the female life cycle: a continuum of vulnerability J. Psychiatry Neuro-sci. 2008;33:331-43.

• 3. Clayton A, Ninan P. Depression or menopause? presentation and manage-ment of major depressive disorder in perimenopausal and postmenopausal women. Prim. Care Companion J. Clin. Psychiatry. 2010;12:1-13. DOI: https://doi.org/10.4088/PCC.08r00747blu

• 4. Deecher D, Andree T, Sloan D, Schechter L. From menarche to menopause: exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology. 2008; 33:3-17. DOI: https://doi.org/10.1016/j.psyneuen.2007.10.006

• 5. Cohen L, Soares C, Vitonis A, Otto M, Harlow B. Risk for new onset of de-pression during the menopausal transition: the harvard study of moods and cy-cles. Arch. Gen. Psychiatry. 2006;63:385-390. DOI: https://doi.org/10.1001/archpsyc.63.4.385

• 6. Freeman E, Sammel M, Lin H, Nelson D. Associations of hormones and men-opausal status with depressed mood in women with no history of depres-sion. Arch. Gen. Psychiatry. 2006;63:375-382. DOI: https://doi.org/10.1001/archpsyc.63.4.375

• 7. Roisin W, Susan R, Emorfia G, Zoe G, Stuart L, Henry B, Jayashri K. Hormo-nal therapies for new onset and relapsed depression during perimenopause. Maturitas. 2012;73:127-33. DOI: https://doi.org/10.1016/j.maturitas.2012.06.011

• 8. Narrow WE. Age and Gender Considerations In Psychiatric Diagnosis : A Research Agenda For DSM-V. 1ª ed. Arlington: Editora American Psychiatric Publishing; 2007.

• 9. Pinkerton J, Guico-Pabia C, Taylor H. Menstrual cycle-related exacerbation of disease. Am. J. Obstet. Gynecol. 2010;202:221-231. DOI: https://doi.org/10.1016/j.ajog.2009.07.061

• 10.Andrade L. Epidemiologia dos transtornos psiquiátricos na mulher. Rev. Psiq. Clín. 2006;33:43-54. DOI: https://doi.org/10.1590/S0101-60832006000200003

• 11. Society for Menstrual Cycle Research Position Statement Naming Women’s Midlife Reproductive Transition. [acessado em

10.2012]. Available from: http://menstruationresearch.org/wp-content/uploads/2012/04/SMCR-Position-statementPerimenopause-and-Menopause-reviewed-final.pdf

• 12. Soares C. Treatment of menopause-related mood disturbances. CNS. Spectr. 2005;10:489-497. DOI: https://doi.org/10.1017/S109285290002318X

• 13. Santoro N, Randolph J. Reproductive hormones and the menopause transi-tion. Obstet. Gynecol. Clin. N. Am. 2011;38:455-466. DOI: https://doi.org/10.1016/j.ogc.2011.05.004

• 14. Connolly K, Thase M. Emerging drugs for major depressive disorder. Expert Opin. Emerg. Drugs. 2012;17:105-26. DOI: https://doi.org/10.1517/14728214.2012.660146

• 15. Current Topics in Behavioral Neuroscience. Pharmacological Treatment of Unipolar Depression. [acessado em 17.10.2012]. Available from: http://link.springer.com/chapter/10.1007%2F7854_2012_208#page-1

• 16. Dunlop B, Binder E, Cubells J. Predictors of remission in depression to indi-vidual and combined treatments (PReDICT): study protocol for a randomized controlled trial. Trials. 2012;13:106. DOI: https://doi.org/10.1186/1745-6215-13-106

• 17. Thase M, Entsuah R, Cantillon M, Kornstein S. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J. Womens Health (Larchmt). 2005;14:609-16. DOI: https://doi.org/10.1089/jwh.2005.14.609

• 18. Marsh W, Deligiannidis K. Sex-related differences in antidepressant re-sponse: When to adjust treatment. Current Psychiatry. 2010;9:25-31.

• 19. Neill JC, Kulkarni J. Biological Basis of Sex Differences in Psychopharma-cology. 1ª Ed. Berlin: Editora Springer‐Verlag; 2011. DOI: https://doi.org/10.1007/978-3-642-20006-9

• 20. Parry B. Optimal management of perimenopausal depression. Int. J. Wom-ens Health. 2010;2:143-51.• 21. Politi M, Schleinitz M, Col N. Revisiting the duration of vasomotor symptoms of menopause: a metaanalysis. J. Gen. Intern. Med. 2008;23:1507-13. DOI: https://doi.org/10.1007/s11606-008-0655-4

• 22. Minuzzi L, Frey B, Soares C. Depression during the menopausal transition: an update on epidemiology and biological treatments. Focus. 2012;10:22-27. DOI: https://doi.org/10.1176/appi.focus.10.1.22

• 23. Soares C, Thase M, Clayton A, Guico-Pabia C, Focht K, Jiang Q, Kornstein S, Ninan P, Kane C, Cohen L. Desvenlafaxine and escitalopram for the treat-ment of postmenopausal women with major depressive disorder. Meno-pause. 2010 ;17:700-11. DOI: https://doi.org/10.1097/gme.0b013e3181d88962

• 24. Wroolie T, Williams K, Keller J, Zappert L, Shelton S, Kenna H, Reynolds M, Rasgon N. Mood and neuropsychological changes in women with midlife depression treated with escitalopram. J. Clin. Psychopharmacol. 2006;26:361-6. DOI: https://doi.org/10.1097/01.jcp.0000227699.26375.f8

• 25. Freeman M, Hill R, Brumbach B. Escitalopram for perimenopausal depres-sion: an open-label pilot study. J. Womens Health (Larchmt). 2006;15:857-61. DOI: https://doi.org/10.1089/jwh.2006.15.857

• 26. Soares C, Arsenio H, Joffe H, Bankier B, Cassano P, Petrillo L, Cohen L. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symp-toms, sleep, and quality of life. Menopause. 2006;13:780-6. DOI: https://doi.org/10.1097/01.gme.0000240633.46300.fa

• 27. Freeman E, Guthrie K, Caan B, Sternfeld B, Cohen L, Joffe H, Carpenter J, Anderson G, Larson J, Ensrud K, Reed S,Newton K, Sherman S, Sammel M, LaCroix A. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011;305:267-74. DOI: https://doi.org/10.1001/jama.2010.2016

• 28. Freedman RR, Kruger ML, Tancer ME. Escitalopram treatment of menopau-sal hot flashes. Menopause. 2011;18:893-6. DOI: https://doi.org/10.1097/gme.0b013e31820ccae9

• 29. Carpenter JS, Guthrie KA, Larson JC, Freeman EW, Joffe H, Reed SD, Ensrud KE, LaCroix AZ. Effect of escitalopram on hot flash

interference: a randomized, controlled trial. Fertil Steril. 2012;97:1399-404. DOI: https://doi.org/10.1016/j.fertnstert.2012.03.001

• 30. Lacroix AZ, Freeman EW, Larson J, Carpenter JS, Joffe H, Reed SD, Newton KM, Seguin RA, Sternfeld B, Cohen L, Ensrud KE. Effects of escitalopram on menopause-specific quality of life and pain in healthy meno-pausal women with hot flashes: A randomized controlled trial. Maturi-tas. 2012;73:361-8. DOI: https://doi.org/10.1016/j.maturitas.2012.09.006

• 31. Defronzo R, Menza M, Allen LA, Marin H, Bienfait KL, Tiu J, Howarth J. Es-citalopram reduces hot flashes in nondepressed menopausal women: A pilot study. Ann. Clin. Psychiatry. 2009;21:70-6.

• 32. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to an-tidepressants: a metaanalysis. J. Clin. Psychopharmacol. 2009;29:259-66. DOI: https://doi.org/10.1097/JCP.0b013e3181a5233f

• 33. Reed SD, Guthrie KA, Joffe H, Shifren JL, Seguin RA, Freeman EW. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. Obstet. Gynecol. 2012;119:527-38. DOI: https://doi.org/10.1097/AOG.0b013e3182475fa4

• 34. Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D, et al. Changes in body weight during pharmacological treatment of depression. Int. J. Neuro-psychopharmacol. 2011;14:367-75. DOI: https://doi.org/10.1017/S1461145710000933

• 35. Wade A, Crawford G, Yellowlees A. Efficacy, safety and tolerability of es-citalopram in doses up to 50 mg in major depressive disorder (MDD): an open-label, pilot study. BMC Psychiatry. 2011;42:1-9. DOI: https://doi.org/10.1186/1471-244X-11-42

• 36. Gartlehner G, Gaynes BN, Hansen RA. Comparative benefits and harms of second-generation antidepressants: Background paper for the American Col-lege of Physicians. Ann. Intern. Med. 2008;149:734-750. DOI: https://doi.org/10.7326/0003-4819-149-10-200811180-00008

• 37. Trkulja V. Is escitalopram really relevantly superior to citalopram intreatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. Croat. Med. J. 2010;51:61-73. DOI: https://doi.org/10.3325/cmj.2010.51.61

• 38. Montgomery S, Hansen T, Kasper S. Efficacy of escitalopram compared with citalopram: A metaanalysis. Int. J. Neuropsychopharmacol. 2011;14:261-8. DOI: https://doi.org/10.1017/S146114571000115X

• 39. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J. Clin. Psychiatry. 2010;71:1088-96. DOI: https://doi.org/10.4088/JCP.10m06018blu

• 40. A Multicenter, Parallel-Group, Randomized, 10-Week, Double-Blind, Place-bo-Controlled Study To Evaluate The Efficacy And Safety Of 50 mg Of DVS SR In The Treatment Of Peri- And Postmenopausal women With Major Depressive Disorder. [acessado em 09.04.2012]. Available from: http://www.clinicaltrials.gov/ct2/home

• 41. Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J. Clin. Psycho-pharmacol. 2010;30:294-9. DOI: https://doi.org/10.1097/JCP.0b013e3181dcb594

• 42. Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan PT, Kane CP. Open-label treatment with desvenlafaxine in postmenopausal women with majordepressive disorder not responding to acute treatment with desvenlafaxine or escitalopram. CNS Drugs. 2011;25:227-38. DOI: https://doi.org/10.2165/11586460-000000000-00000

• 43.Wyrwich KW, Spratt DI, Gass M, Yu H, Bobula JD. Identifying meaningful differences in vasomotor symptoms among menopausal women. Meno-pause. 2008;15:698-705. DOI: https://doi.org/10.1097/gme.0b013e31815f892d

• 44. Speroff L, Gass M, Constantine G, Olivier S; Study 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vaso-motor symptoms: a randomized controlled trial. Obstet. Gynecol. 2008;111:77-87. DOI: https://doi.org/10.1097/01.AOG.0000297371.89129.b3

• 45. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S. Desvenlafax-ine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am. J. Obstet. Gynecol. 2009;238:1-10. DOI: https://doi.org/10.1016/j.ajog.2008.10.057

• 46. Pinkerton JV, Constantine G, Hwang E, Cheng RF; for the Study 3353 In-vestigators. Desvenlafaxine compared with placebo for treatment of menopau-sal vasomotor symptoms: a 12-week, multicenter, parallelgroup, randomized, double-blind, placebo-controlled efficacy trial. Menopause. [periódico online] 2012; [acessado em 02.09.2012]. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/23010882

• 47. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S; Study 319 Investigators. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am. J. Obstet. Gynecol. 2009;200:1-10. DOI: https://doi.org/10.1016/j.ajog.2008.09.877

• 48. Bouchard P, Panay N, de Villiers TJ, Vincendon P, Bao W, Cheng RJ, Constantine G. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric. 2012;15:12-20. DOI: https://doi.org/10.3109/13697137.2011.586445

• 49. Cheng RJ, Dupont C, Archer DF, Bao W, Racketa J, Constantine G, Pickar JH. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric. 2012;10:1-11. DOI: https://doi.org/10.3109/13697137.2012.672495

• 50. Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J. Clin. Psycho-pharmacol. 2011;31:569-76. DOI: https://doi.org/10.1097/JCP.0b013e31822c0a68

• 51. Tourian KA, Leurent C, Graepel J, Ninan PT. Desvenlafax-ine and weight change in major depressive disorder. Prim. Care Companion J. Clin. Psychiatry. 2010;12:1-8. DOI: https://doi.org/10.4088/PCC.08m00746blu

• 52. Ferguson JM, Tourian KA, Rosas GR. High-dose desvenlafaxine in outpa-tients with major depressive disorder. CNS Spectr. 2012;17:121-30. DOI: https://doi.org/10.1017/S1092852912000508

• 53. Coleman KA, Xavier VY, Palmer TL, Meaney JV, Radalj LM, Canny LM.An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. CNS Spectr. 2012;17:131-41. DOI: https://doi.org/10.1017/S1092852912000648

• 54. Marsh WK, Deligianiddis KM. Sex-related differences in antidepressant re-sponse: When to adjust treatment. Current Psychiatry. 2010; 9:25-31.

• 55. Weinberger AH, McKee SA, Mazure CM. Inclusion of women and gender-specific analyses in randomized clinical trials of treatments for depression. J. Womens Health (Larchmt). 2010;19:1727-32. DOI: https://doi.org/10.1089/jwh.2009.1784

• 56. Simon GE, Perlis RH. Personalized medicine for depression: Can we match patients with treatments? Am. J. Psychiatry. 2010;167:1445-1455. DOI: https://doi.org/10.1176/appi.ajp.2010.09111680

• 57. Abramowicz M. Drugs for menopausal symptoms. Med. Lett. Drugs Ther. 2012;54:41-2.

• 58. Santoro NF, Clarkson TB, Freedman RR, FughBerman AJ, Loprinzi CH, Reame NC. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause. 2004;11:11-33. DOI: https://doi.org/10.1097/01.GME.0000108177.85442.71

• 59. Cobin RH, Futterweit W, Ginzburg SB, Goodman NF, Kleerekoper M, Licata AA et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr. Pract. 2006;12:315-337. DOI: https://doi.org/10.4158/EP.12.3.315

• 60. Umland EM. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms. J Manag Care Pharm. 2008;14:14-19. DOI: https://doi.org/10.18553/jmcp.2008.14.S3-A.14

• 61. U.S. Department of Health and Human Services - Food and Drug Admin-istration. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms - recommendations for clinical evaluation. [acessado em 02.12.2012]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135338.pdf

• 62. European Medicines Agency. Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. [acessado em 03.12.2012]. Available from: http://www.tga.gov.au/pdf/euguide/emea002197enrev1.pdf

Downloads

Published

2013-02-28

How to Cite

1.
Rocha R, Rennó Jr J, Ribeiro HL, Cantilino A, Ribeiro J de AM, Demarque R, Cavalsan JP, Valadares GC, Silva AG da. Treatment of Depression in the Climacterium. Debates em Psiquiatria [Internet]. 2013 Feb. 28 [cited 2024 Dec. 22];3(1):18-25. Available from: https://revistardp.org.br/revista/article/view/338

Conference Proceedings Volume

Vol. 3 No. 1 (2013)

Section

Review Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.

Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:

  • Share — copy and redistribute the material in any medium or format
  • Adapt — remix, transform, and build upon the material

The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.

No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Crossref
Scopus
Google Scholar
Europe PMC

Plaudit

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>